Ipamorelin

Ipamorelin is a selective growth hormone secretagogue that stimulates pulsatile GH release without raising cortisol or prolactin; the strongest community interest is in muscle growth, fat loss, sleep, and recovery, with only scattered reports on injury repair. Clinician protocols converge on 200–300 mcg subcutaneous at bedtime as entry-level dosing, with some scaling to 1 mg daily for a stronger IGF-1 response; cycles run 8–12 weeks, though continuous use is also described. The off-label evidence base is thinner than the discourse suggests, and most exploratory indications lack posted results.

Ipamorelin

Research Evidence

Evidence shape

Ipamorelin sits in the low-evidence tier: the strongest human data reach Phase 2 and are limited to a pair of single trials in gastrointestinal dysmotility and postoperative ileus. Only one publication is linked to the two registered trials, and the remainder of the mapped research is animal-only or long-tail single-trial work without posted replication. The absence of larger studies, posted replication, or further follow-up is the signal; what exists has not moved past exploratory status.

Depthhow much
2 registered trials
2 completed
Breadthhow many areas
3 indications mapped
2 thin / exploratory · 1 animal-only · 2 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 2
1 linked publication on registered trials
Breadth and depth11 rows captured
Human
direct clinical signal
2
Animal
translational support
8
In vitro
mechanistic support
1
HighMediumLow

Anecdotal efficacy

Side effects

Clinical research side effects

Clinical safety table not projected yet.

Anecdotal side effects

Price

1
Natty Peptides
UK
2400 mg
$38.94
$0.013/mg
2
Nextgenpeps
US
10 mg
$0.79
$0.079/mg
3
High Purity Peptides
HK
100 mg
$70.00
$0.7/mg
4
Nexaph
US
100 mg
$178.00
$1.78/mg
5
Prism Aminos
US
50 mg
$99.00
$1.98/mg
6
OC.PEPS
US
10 mg
$20.00
$2/mg

price offers can be sorted by column

1-6 of 134

Dosing & Protocol

How Ipamorelin is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 7
Typical dose
50 µg25 µg – 1 mg
25 µg
50 µg
125 µg
500 µg
1 mg
Frequency
daily
Timing
unspecified
Route
IV
Cycle
unspecified

Across 7 completed trials, registry dosing was 25 µg–1 mg daily IV.

2 sources
Clinician practice
Doctor & published-protocol guidance · n = 4
Typical dose
300 µg200 µg – 1 mg
25 µg
50 µg
125 µg
500 µg
1 mg
Frequency
BID
Timing
unspecified
Route
subQ
Cycle
unspecified

Clinician protocols dose 200 µg–1 mg BID subQ (4 sources).

4 sources
Anecdotal
Community-reported real-world use · n = 31
Typical dose
150 µg
25 µg
50 µg
125 µg
500 µg
1 mg
By reported cadence
Schedule unstated150 µg · n=1
Frequency
unspecified
Timing
unspecified
Cycle
unspecified

Reported doses span 150 µg, most commonly 150 µg; most posters do not state a schedule.

1 source

Peptide Deep Dive

Peptide Deep Dive is not projected for this peptide yet.

Peptide feedback

0 forum replies

Live community discussion for Ipamorelin, shown here in the site layout and continued on the TVR forum.

Add feedback

No peptide feedback yet

Start the peptide feedback thread on the TVR forum.